Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (June 2017)

23 slides from Titan Pharmaceuticals's investor presentation, Jun 6, 2017

  1. Slide 1: Titan Pharmaceuticals Corporate Presentation May 2017

    TITAN PHARMACEUTICALS CORPORATE PRESENTATION MAY 2017 © 2017 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP

  2. Slide 2: Forward-Looking Statements

    FORWARD - LOOKING STATEMENTS The presentation may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Reference is made in particular to the description of our plans and objectives for futur

  3. Slide 3: Company Snapshot

    COMPANY SNAPSHOT 3 • Focus on proprietary therapeutics for select chronic diseases • ProNeura TM drug delivery platform provides long - term, continuous, non - fluctuating medication levels • FDA approved Probuphine ® (buprenorphine) implant – six - month maintenance treatment of opioid addiction •

  4. Slide 4: ProNeura: Long-Term Drug Delivery Platform

    PRONEURA: LONG - TERM DRUG DELIVERY PLATFORM 4 • Active pharmaceutical ingredient (API) uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Controlled rate of drug delivery and virtually 100% bioavailability EVA PO

  5. Slide 5: ProNeura Implant Administration

    PRONEURA IMPLANT ADMINISTRATION 5 • Inserted subdermally in the inner side of the upper arm by a certified health care provider • Drug is released continuously into patient's body through the process of dissolution • Results in a stable level of medication in the blood, avoiding peaks and troughs of

  6. Slide 6: Titan ProNeura Product Pipeline

    TITAN PRONEURA PRODUCT PIPELINE 6 CANDIDATE INDICATION DEVELOPMENT STAGE Probuphine ® (United States) Opioid Addiction Probuphine ® (European Union) Opioid Addiction Ropinirole Implant Parkinson’s Disease T3 Implant Hypothyroidism Feasibility evaluation of additional compounds in other chronic disea

  7. Slide 7: Probuphine (Buprenorphine) Implant

    PROBUPHINE (BUPRENORPHINE) IMPLANT 7 Probuphine (buprenorphine) implant is the first ProNeura based product approved by the FDA in M ay 2016 for the maintenance treatment of opioid addiction EFFICACY Effective in reducing illicit opioid use SAFETY Non - fluctuating drug exposure over six months may

  8. Slide 8: Opioid Addiction: Opportunity for Probuphine

    OPIOID ADDICTION: OPPORTUNITY FOR PROBUPHINE 8 • Major epidemic in the U.S. with an estimated 2.5 million people affected with this disease • Buprenorphine treatment is the gold standard as an effective, safer, and more convenient treatment option with 2016 annual U.S. sales of approximately $2.2 bi

  9. Slide 9: Probuphine Development & Commercialization Update

    PROBUPHINE DEVELOPMENT & COMMERCIALIZATION UPDATE 9 Partnership with Braeburn Pharma for U.S. and Canada * signed in December 2012 * Braeburn has sublicensed Canadian rights to Knight Therapeutics Milestone payments • Upfront: $15.75 million • Approval Milestone: $15 million • Sales Milestones: up t

  10. Slide 10: Probuphine: U.S. Commercialization Update

    PROBUPHINE: U.S. COMMERCIALIZATION UPDATE* 10 • More than 2,500 health care providers certified under the Probuphine REMS program • Over 70 payors signaled intention to cover Probuphine, including Medicare, Medicaid & VA programs • Braeburn has devoted additional resources to streamlining the paperw

  11. Slide 11: Probuphine: Gaining Awareness

    PROBUPHINE: GAINING AWARENESS 11 Recent Probuphine coverage includes: • New York Times • Fortune Magazine • CNBC • CBS • Drug Delivery Business News • WPIX - TV (New York, NY) • WMUR Channel 9 (Manchester, NH) • WHDT TV (Stuart, FL) Industry Recognition: • Popular Science ‘Best of What’s New’ • Stev

  12. Slide 12: Probuphine: Ex-U.S. Partnering Plans

    PROBUPHINE: EX - U.S. PARTNERING PLANS 12 • Advancing ex - U.S. opportunities for regulatory approval and commercial licensing • Progressing discussions with interested companies in EU and other select regions • Received positive scientific and regulatory guidance during December 2016 meetings with

  13. Slide 13: Parkinson's Disease Overview

    PARKINSON’S DISEASE OVERVIEW • Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function • Treated with drugs designed to replace or mimic dopamine in the brain • After several years of treatment , these drugs lose benefit and trigger seri

  14. Slide 14: Parkinson's Disease – Therapeutics Market

    PARKINSON’S DISEASE – THERAPEUTICS MARKET 14 * GlobalData; **Parkinson’s Action Network, National Center for Health Statistics; “The Current and Projected Economic Burden of Parkinson’s Disease in the United States” Movement Disorders, March 2013 Based on information from Titan and other sources bel

  15. Slide 15: ProNeura Parkinson's Disease Program

    PRONEURA PARKINSON’S DISEASE PROGRAM 15 • Ropinirole (Requip®), a dopamine agonist marketed by GSK for PD • Evaluated in a Parkinsonian animal model using ProNeura drug delivery platform • Results presented in June 2015 - 19th International Congress of Parkinson's Disease and Movement Disorders • Su

  16. Slide 16: ProNeura Parkinson's Disease Program: Ropinirole Implant Status

    PRONEURA PARKINSON’S DISEASE PROGRAM 16 Ropinirole implant program status • Implant formulation selected for clinical development • Non - clinical development program defined and initial clinical study design established • Investigational New Drug Application submitted to the FDA in January 2017 • R

  17. Slide 17: Hypothyroidism Disease Overview

    HYPOTHYROIDISM DISEASE OVERVIEW • Thyroid gland does not make enough thyroid hormone to meet body’s need • Typical treatment consists of synthetic prohormone thyroxine (T4) given orally once a day, which is converted by the body to the active triiodothyronine (T3) • Oral T3 treatment is effective, b

  18. Slide 18: ProNeura Hypothyroidism Program Status

    PRONEURA HYPOTHYROIDISM PROGRAM STATUS 18 • Completed initial formulation development of the implant and conducted in - vitro and in - vivo drug release studies to further define implant formulation • In - vivo non - clinical studies conducted evaluating implant formulations for drug release charact

  19. Slide 19: Titan Executive Management

    TITAN EXECUTIVE MANAGEMENT 19 Marc Rubin, M . D . Executive Chairman & Director • 10 years with Titan • Former Head of Global R&D and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 26 years in the pharmaceutical industry follow

  20. Slide 20: Titan Pharmaceuticals Summary

    TITAN PHARMACEUTICALS SUMMARY • ProNeura - Unique and compelling long - term drug delivery platform • Probuphine - Only product on market to provide six - month, continuous, non - fluctuating blood levels of buprenorphine for maintenance treatment of opioid addiction • Attractive U . S . partnership

  21. Slide 21: Thank You. Questions?

    THANK YOU. QUESTIONS? © 2017 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP

  22. Slide 22: Probuphine: Risk Evaluation & Mitigation Strategy

    PROBUPHINE: RISK EVALUATION & MITIGATION STRATEGY Appendix

  23. Slide 23: Probuphine: Risk Evaluation & Mitigation Strategy

    PROBUPHINE: RISK EVALUATION & MITIGATION STRATEGY Training and Certification – Providers who prescribe and implant Probuphine will: • Attend Live Training: Lecture and Practicum • Complete the Probuphine REMS P rogram K nowledge Assessment • Be enrolled in the Probuphine REMS program • Providers who

Titan Pharmaceuticals — Investor Presentation (June 2017) on 6ix